Table 1.
Summary of Target FISH results on 40 patients
| No. | Sex/Age | PC%a | BioViewb | Del(17p)/TP53 | t(4;14) | t(14;16) | +1q21 | Others |
|---|---|---|---|---|---|---|---|---|
| 1 | M/52 | 26 % | 14–16 % (10323–15875) | Neg (230)c | 38 % + (74) | Neg (201) | 30 % + (180) | |
| 2 | F/80 | 15 % | 3–4 % (9605–13508) | Neg (89) | Neg (61) | Neg (71) | Neg (71) | Normal cytogenetics |
| 3 | M/69 | 12 % | 3–4 % (8880–11094) | Neg (84) | Neg (46)g | Neg (40)g | Neg (62) | |
| 4 | M/81 | 43 % | No record | Neg (253) | Neg (188) | Neg (175) | Neg (200) | 5/9/15 60 % + (235) |
| 5 | M/64 | 15 % | 58–64 % (11912–17007) | Neg (159) | Neg (153) | Neg (156)g | Neg (155) | 5/9/15 Neg (84) |
| 6 | M/70 | 17 % | 4–7 % (7132–7616) | Neg (63) | Neg (53)g | Neg (51)g | 80 % + (53) | 5/9/15 Neg (61) |
| 7 | F/52 | 35 % | 8–12 % (7750–8981) | Neg (159) | 90 % + (112)g | Neg (102)g | 65 % + (167) | Cytogeneticsd: hypodiploid 78.5 %, hyperdiploid 7 %, normal 14.5 % |
| 8 | F/72 | 13 % | 42–55 % (11829–14627) | Neg (32) | Neg (35) | Neg (71) | Neg (54) | |
| 9 | F/71 | 17 % | 7–9 % (8667–11174) | Neg (82) | 70 % + (54) | Neg (37) | 50 % + (65) | Normal cytogenetics |
| 10 | M/61 | 65 % | 17–24 % (10289–13997) | Neg (135) | Neg (94)g | Neg (98)g | 90 % + (145) | |
| 11 | M/54 | 15 % | 15–22 % (12898–19268) | Neg (141) | 80 % + (87) | Neg (84) | Neg (113) | 5/9/15 Neg (171) |
| 12 | M/47 | 100 % | 50–59 % (10424–12419) | 50 % + (132) | Neg (144)g | Neg (107)g | Neg (156) | |
| 13 | M/59 | 60 % | 10–12 % (9514–13412) | Neg (154) | Neg (133)g | Neg (128)g | Neg (140) | t(11;14) 90 %+; normal cytogenetics |
| 14 | M/81 | 22 % | 50–52 % (10110–15964) | Neg (140) | 60 % + (78)g | Neg (111)g | 85 % + (172) | 5/9/15 Neg (101) |
| 15 | F/67 | 45 % | 21–27 % (6066–7366) | Neg (163) | 90 % + (145) | Neg (136) | 85 % + (183) | 5/9/15 Neg (157) |
| 16 | M/58 | No record | 8–9 % (6666–8923) | Neg (250) | Neg (192)g | Neg (188)g | Neg (224) | t(11;14) 25 % + (228) |
| 17 | F/70 | 51 % | 13–17 % (7469–8551) | Neg (183) | Neg (137)g | Neg (118)g | 85 % + (162) | Normal cytogenetics |
| 18 | F/53 | 23 % | 10 % (2719–4195) | Neg (198) | Neg (146) | Neg (80) | Neg (106) | 5/9/15 Neg (87) |
| 19 | M/76 | 70 % | 6–7 % (4145–5686) | Neg (108) | Neg (89) | Neg (102) | Neg (101) | IgH Neg (71) |
| 20 | M/61 | 49 % | 17–19 % (4210–5352) | Neg (170) | Neg (126) | Neg (119) | 85 % + (172) | |
| 21 | M/61 | 20 % | 24–29 % (9895–11736) | Neg (145) | Neg (122) | Neg (87) | Neg (142) | Normal cytogenetics |
| 22 | F/48 | 59 % | 6–9 % (6942–7583) | 40 % + (172) | 65 % + (110) | Neg (111) | 55 % + (154) | Normal cytogenetics |
| 23 | F/56 | 100 % | 3–8 % (4400–6203) | Neg (123) | Neg (149)g | Neg (118) | 65 % + (158) | |
| 24 | F/55 | 84 % | 3–6 % (9304–10362) | Neg (141) | Neg (148) | Neg (107) | Neg (82) | t(11;14) 85 % + (121) |
| 25 | M/52 | 74 % | 11–23 % (10024–12394) | Neg (158) | 85 % + (100) | Neg (135)g | 90 % + (162) | Cytogeneticse: hypodiploid clone, der(4)t(1;4)(q21;p16) and add(7p) |
| 26 | F/56 | 35 % | 11–17 % (10247–12375) | Neg (100) | Neg (166) | Neg (140)g | Neg (117) | |
| 27 | F/55 | 73 % | 10–17 % (3419–5581) | Neg (186) | Neg (167) | Neg (142) | Neg (171) | |
| 28 | F/57 | 15 % | 6–8 % (5191–6330) | Neg (102) | Neg (122) | Neg (102) | Neg (100) | |
| 29 | F/69 | 16 % | 25–32 % (7923–12371) | Neg (172) | Neg (143)g | Neg (104)g | Neg (173) | |
| 30 | M/58 | 19 % | 3–5 % (6385–8924) | Neg (213) | Neg (169) | Neg (154) | Neg (208) | |
| 31 | F/66 | 29 % | 7–11 % (7383–9153) | Neg (149) | 70 % + (73) | Neg (108)g | 80 % + (127) | |
| 32 | F/56 | 15 % | 7–12 % (11256–13079) | Neg (146) | Neg (117)g | Neg (93) | Neg (150) | |
| 33 | M/64 | 13 % | 4–6 % (11082–12940) | Neg (118) | Neg (100) | Neg (98) | Neg (101) | t(11;14) 40 % + (149); cytogeneticsf: loss of Y chromosome |
| 34 | F/67 | 21 % | 6–13 % g11872–14598) | Neg (159) | 70 % + (104) | Neg (118)g | 95 % + (136) | |
| 35 | F/89 | 12 % | 3–5 % (11793–14289) | Neg (121) | Neg (134) | Neg (102) | Neg (102) | Normal cytogenetics |
| 36 | F/50 | 56 % | 14–17 % (10614–13489) | Neg (140) | Neg (143) | Neg (111) | 60 % + (137) | |
| 37 | M/60 | 50 % | 24–27 % (10633–13622) | Neg (165) | Neg (121) | Neg (117) | 83 % + (143) | |
| 38 | M/79 | 20 % | 6–10 % (13896–15969) | Neg (125) | Neg (96) | Neg (121)g | 80 % + (144) | 80 % trisomy TP53 |
| 39 | F/67 | 53 % | 32–38 % (13807–17047) | Neg (162) | 63 % + (123) | Neg (103) | 63 % + (104) | |
| 40 | M/69 | 57 % | 6–13 % (12778–15272) | Neg (158) | Neg (127) | Neg (148) | Neg (158) |
Key:
aThe PC% refers to the plasma cell percentage in the bone marrow aspirate as enumerated on microscopic examination
bThe BioView data refers to the percentage of cells in the plasma cell category as recognized by the automated image capture and analysis system before manual re-classification. The number in the parentheses refers to the total number of cells analyzed by the automated image capture and analysis system on the slide. Both are reported as a range of figures obtained from the 4 slides
cThe number in parenthesis is the actual number of re-classified plasma cells with optimal FISH signals on which the positive or negative result is based. This figure is also indicated on the pathology report for each FISH probe
d26 ~ 45,XX,t(4;14)(p16;q32)[33]/48 ~ 159,XX[3]/46,XX[6]
e43 ~ 44,XY,+3[2],der(4)t(1;4)(q21;p16)[2],add(7)(p13)[2],+7 ~ 8mar[2][cp2]/46,XY[4]
f45,X,-Y[3]/46,XY[15]
gDenotes the incidental finding of secondary abnormalities i.e. monosomy of deletion of chromosomes 4, 14 or 16; trisomy or amplification of chromosomes 4, 14 or 16